Objective： To evaluate the clinical efficacy and safety of Tianqijiangtang Capsule （TG） during the treatment ofimpaired glucose tolerance （IGT）. Methods： Using Chinese words of “impaired glucose tolerance, abno...Objective： To evaluate the clinical efficacy and safety of Tianqijiangtang Capsule （TG） during the treatment ofimpaired glucose tolerance （IGT）. Methods： Using Chinese words of “impaired glucose tolerance, abnormalglucose tolerance, IGT” and “TG” as search terms, China National Knowledge Infrastructure, VIP, Wanfang Dataand Pubmed were searched from database inception until October 2017. All the controlled clinical researches on thetreatment of IGT by TG meeting the inclusion and exclusion criteria were retrieved and analyzed by ReviewManager 5.3 software. Results： A total of 7 articles including 1082 participants were enrolled. Meta-analysisshowed that the OR value of inversion rate was 2.17, 95% CI （1.65, 2.84）. Weighted mean difference （WMD） valueof fasting plasma glucose was -0.25, 95% CI （-0.39, -0.11）. After 2 h, the WMD value of serum glucose was -0.73,95% CI （-0.96, -0.51）, all of which were better than these of control group. The OR value of progression rate （type2 diabetes mellitus） was 0.44, 95% CI （0.32, 0.59）, less than the control group. All of the differences werestatistically significant. No hepatic and renal toxicity case was reported. Only 1 article reported adverse reactions inthe course of treatment. Conclusion： TG could treat IGT effectively, delay and even invert the progress of IGT, butits security still needed further discussion.展开更多
文摘Objective： To evaluate the clinical efficacy and safety of Tianqijiangtang Capsule （TG） during the treatment ofimpaired glucose tolerance （IGT）. Methods： Using Chinese words of “impaired glucose tolerance, abnormalglucose tolerance, IGT” and “TG” as search terms, China National Knowledge Infrastructure, VIP, Wanfang Dataand Pubmed were searched from database inception until October 2017. All the controlled clinical researches on thetreatment of IGT by TG meeting the inclusion and exclusion criteria were retrieved and analyzed by ReviewManager 5.3 software. Results： A total of 7 articles including 1082 participants were enrolled. Meta-analysisshowed that the OR value of inversion rate was 2.17, 95% CI （1.65, 2.84）. Weighted mean difference （WMD） valueof fasting plasma glucose was -0.25, 95% CI （-0.39, -0.11）. After 2 h, the WMD value of serum glucose was -0.73,95% CI （-0.96, -0.51）, all of which were better than these of control group. The OR value of progression rate （type2 diabetes mellitus） was 0.44, 95% CI （0.32, 0.59）, less than the control group. All of the differences werestatistically significant. No hepatic and renal toxicity case was reported. Only 1 article reported adverse reactions inthe course of treatment. Conclusion： TG could treat IGT effectively, delay and even invert the progress of IGT, butits security still needed further discussion.
